Consent and privacy in pharmacogenetic testing
作者： John A. Robertson
DOI: 10.1038/90032
关键词: Intensive care medicine 、 Pharmacology 、 Pharmacogenetic Test 、 Pharmacogenetics 、 Disease 、 Informed consent 、 Biology 、 Genetics
摘要: The clinical use of pharmacogenetic drugs will require that a sample patient's DNA be tested before drug is prescribed. Although tests pose fewer risks than genetic for disease mutations, they might still reveal personal information could used adversely to interests. Informed consent and privacy test results may essential in most uses drugs.
nature.com
sci-hub.se 参考文章(8)
J. Kastner, ASTRONOMY: Orion Sheds New Light on Star and Planet Formation Science. ,vol. 291, pp. 57- 58 ,(2001) , 10.1126/SCIENCE.10.1126/SCIENCE.1056553
Allen D. Roses, Pharmacogenetics and the practice of medicine. Nature. ,vol. 405, pp. 857- 865 ,(2000) , 10.1038/35015728
Watson Ms, Holtzman Na, Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Journal of child and family nursing. ,vol. 2, pp. 388- ,(1999)
Suzanne Feetham, Comments on the Secretary's Advisory Committee on genetic testing document: A public consultation on oversight of genetic tests, January 27, 2000, Baltimore, Maryland * Nursing Outlook. ,vol. 48, pp. 137- 139 ,(2000) , 10.1016/S0029-6554(00)70010-8
Abel Torres, The Use of Food and Drug Administration Approved Medications for Unlabeled (Off-Label) Uses Archives of Dermatology. ,vol. 130, pp. 32- 36 ,(1994) , 10.1001/ARCHDERM.1994.01690010036003
E. Marshall, CLINICAL RESEARCH: Company Plans to Bank Human DNA Profiles Science. ,vol. 291, pp. 575a- 575 ,(2001) , 10.1126/SCIENCE.291.5504.575A
Assessing Genetic Risks: Implications for Health and Social Policy National Academies Press (US). ,(1994) , 10.17226/2057
Standards for Privacy of Individually Identifiable Health Information Auerbach Publications. ,(2001) , 10.1201/9781420000177.CH38